Related Experiment Video
Updated: Oct 8, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The year in cardiovascular medicine 2021: dyslipidaemia
Lale Tokgozoglu1, Carl Orringer2, Henry N Ginsberg3
1Department of Cardiology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100 Ankara, Turkey.
Abstract:
The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.
Insights
Recent advances in clinical lipidology focus on lowering LDL cholesterol and triglycerides. New therapies targeting novel pathways and lipoprotein(a) are emerging, promising personalized lipid-lowering treatments.
Area of Science:
- Clinical lipidology
- Cardiovascular research
- Pharmacology
Background:
- Lipid management is crucial for cardiovascular health.
- Genetic studies have identified novel therapeutic targets.
- Triglyceride-rich lipoproteins and Lp(a) are increasingly recognized as atherogenic.
Purpose of the Study:
- To review recent advancements in clinical lipidology.
- To highlight emerging therapies for lipid lowering.
- To discuss the potential for personalized lipid management.
Main Methods:
- Review of recent clinical lipidology literature.
- Analysis of genetic studies identifying novel pathways.
- Evaluation of emerging therapeutic agents for lipid disorders.
Main Results:
- Exploration of diverse mechanisms to lower LDL cholesterol.
- Renewed focus on triglyceride-rich lipoproteins and Lp(a) with new treatments.
- Development of targeted therapeutics showing significant Lp(a) reduction.
Conclusions:
- The field of lipidology has expanded with new therapeutic options.
- Personalized lipid-lowering strategies will be enhanced by upcoming outcome data.
- Novel agents offer potential for more effective cardiovascular risk reduction.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiomyopathy V: Interprofessional Care

